C. Steele

Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.

H. Linden, G. Hortobagyi, L. Pusztai, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma

M. Salto‐Tellez, R. Fitzgerald, R. Turkington, 2019, Gut.

Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology.

I. Mills, D. Neal, H. Pandha, 2017, European urology.

Dexamethasone alone and in combination with desipramine, phenytoin, valproic acid or levetiracetam interferes with 5-ALA-mediated PpIX production and cellular retention in glioblastoma cells

R. Rovin, C. Steele, R. Winn, 2016, Journal of Neuro-Oncology.

Quantification of Protoporphyrin IX Accumulation in Glioblastoma Cells: A New Technique

R. Rovin, C. Steele, R. Belton, 2014, ISRN surgery.

A genetic model for central chondrosarcoma evolution correlates with patient outcome

Christopher Davies, P. Van Loo, L. Alexandrov, 2021, Genome Medicine.

Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy

I. Mills, D. McArt, S. McDade, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Analytical validation of a prognostic prostate cancer gene expression assay using formalin fixed paraffin embedded tissue

E. Kay, R. Kennedy, D. Harkin, 2018, BMC Medical Genomics.